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The extract from roasted chicory (Cichorium intybus L.; 菊苣 jú jù) root (chicory root extract), which
contains inulin-type fructans, has favorable effects including antihyperglycemic and antidyslipidemic
effects and the improvement of bowel movement. In this study, we examined the effects of chicory root
extract on blood glucose, lipid metabolism, and fecal properties in 47 healthy adult participants in a
randomized, double-blind, placebo-controlled study. The participants were divided into a test group that
drank chicory root extract and a placebo group that drank nonchicory root extract (ingesting 300 mL
daily for 4 weeks). We performed hematological examinations and body composition measurements,
and administered a visual analog scale (VAS) questionnaire for fecal properties at the baseline (Week 0)
and after the intervention (Week 4) for the two groups. Although no signiﬁcant differences in fasting
plasma glucose or insulin were observed, hemoglobin A1c was found to decrease by ingesting chicory
root extract. No intergroup differences in the levels of lipid metabolism parameters were observed.
However, the level of adiponectin was signiﬁcantly improved in the chicory root extract group when the
baseline and postintervention values were compared. In addition, chicory root extract tends to improve
the VAS score for fecal properties. These results suggest that chicory root extract could delay or prevent
the early onset of diabetes mellitus and improve bowel movements.
Copyright © 2014, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. All rights reserved.1. Introduction triglyceride (TG) levels, reduced high-density lipoprotein-choles-Lifestyle-related diseases such as obesity, dyslipidemia, type 2
diabetes, and hypertension are widespread and are becoming more
prevalent globally. In 2004, the U.S. National Heart, Lung, and Blood
Institute, in collaboration with the American Heart Association,
convened a conference to deﬁne metabolic syndrome.1 Metabolic
syndrome is a complex condition, consisting of interrelated risk
factors for cardiovascular disease and diabetes. These risk factors
include dysglycemia, increased blood pressure, elevatedanagement and Informatics,
, Ebetsu 069-8585, Hokkaido,
ihira).
for Food and Biomolecules,
molecules, National Taiwan Univeterol (HDL-Cho) levels, and obesity.2 A previous study showed that
functional foods can be protective against the occurrence of several
diseases.3 It is thus important to investigate the utility of functional
foods and their bioactive components to improve and prevent
lifestyle-related diseases.
chicory (Cichorium intybus L.; 菊苣 jú jù) is a major crop in
northwestern Europe, and its roots are a rich source of the dietary
ﬁber inulin.4 Chicory roots are used in the preparation of a bitter
drink as a substitute for coffee in France and Japan, for example.
People of all ages can drink the extract from chicory root, because it
has noncaffeine ingredients. Chicory inulin also has the potential to
replace dietary fat, resulting in decreased calorie intake. When
inulin is mixed with water or any other aqueous liquid, it forms a
colloidal suspension providing a white, creamy emulsion.5
Inulin, one of the fructooligosaccharides, is a linear fructose poly-
mer with b(2/1) glycosidic linkages. Inulin is nondigestible, fullyrsity. Production and hosting by Elsevier Taiwan LLC. All rights reserved.
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bacteria and fungi. Some of the plants containing inulin are leeks,
onions, garlic, asparagus, Jerusalem artichokes, yacon, and chicory.7
Inulin has various pharmacological effects. For example, the
addition of inulin to a moderately high-carbohydrate low-fat diet
has a beneﬁcial effect on plasma lipids by decreasing hepatic
lipogenesis and plasma triacylglycerol concentrations.8 In a clinical
study of women with type 2 diabetes, inulin supplementation
(10 g/d) for 2 months improved fasting plasma glucose (FPG), in-
sulin, and hemoglobin A1c (HbA1c) levels, and decreased malon-
dialdehyde levels compared with maltodextrin supplementation.9
Another study reported that ingestion of inulin (12 g/d) for
2 weeks was well tolerated by adult participants and led to a sig-
niﬁcant improvement of bowel movements with a minimum effect
on fecal microﬂora, however, a slight increase in Biﬁdobacterium
and Lactobacillus was noted in participants who had average fecal
levels of Biﬁdobacterium and low fecal frequency.10
These ﬁndings suggest that chicory root, which is rich in inulin,
may help counteract metabolic syndrome; a cluster of conditions
characterized by hyperglycemia and hyperlipidemia. However, very
few clinical studies have assessed the effects of chicory root. Here
we evaluated whether the ingestion of the extract from roasted
chicory root can improve hyperglycemia, dyslipidemia, and bowel
movements in an adult population.
2. Material and methods
2.1. Test meal preparation
The composition of the extract from roasted chicory root
(chicory root extract) used in this study is presented in Table 1.
Chicory was harvested from Tenshin Farm, Furano, Hokkaido,
Japan. The test meal was prepared by drying, roasting, and crushing
the chicory root using a conventional method. The production and
packing were carried out at Tenshin Farm in a quality-controlled
manufacturing plant in compliance with the Food Sanitation Act
(the Ministry of Health, Labor, and Welfare of Japan).
The participantswere instructed to ingest 300mL/d of chicory root
extract (containing0.25g inulin/100mL)or aplacebodrink (barley tea
containing 10% coffee to imitate the bitter taste of the chicory root
extract drink) in two or three parts per day. The reason for choosing
barley tea as the placebo is that barley tea almost does not affect hu-
man health.11 The participants themselves prepared these drinks
every dayas follows: 10 g of chicory root or placebo leaveswere put in
a pot, and 350 mL of hot water was poured over the leaves. It was
revealed that chicory inulin has various degrees of polymerization.7
2.2. Study participants
Forty-seven volunteers (8 males and 39 females; age,
33e70 years) were enrolled in this study. None of the participantsTable 1
Composition of chicory root extract compared with placebo per 100 mL.
Component Chicory Placebo
Calories (kcal) 8 4
Water (g) 97.8 99.1
Proteins (g) 0.1 0.1
Lipids (g) 0.1 0.1
Carbohydrates (g) 1.9 0.9
Ash (g) 0.2 0.1
Sodium (mg) 1.6 e
Inulin (g)a 0.25 e
Total fructan (g) 0.6 e
Polyphenol (g) 0.09 0.03
a The inulin content was calculated as total fructan e fructooligosaccharide.had a recent history of gastrointestinal disorders, pregnancy, sig-
niﬁcant disease, surgery, severe allergic reaction to food, or current
use of any medication including antihypertensive medication. The
age, body weight, height, body mass index (BMI), and body fat
percentage of the participants are presented in Table 2.
The clinical intervention was carried out as a randomized,
double-blind, placebo-controlled trial. At randomization, the 47
eligible participants were randomly and blindly assigned to one of
the two groups: the test group that drank chicory root extract drink,
and the placebo group that drank the placebo drink.
Hematological examinations and body composition (body
weight, BMI, and body fat rate) measurements were performed,
and a visual analog scale (VAS) questionnaire for fecal properties
was administered at the baseline (Week 0) and after the inter-
vention (Week 4) for the two groups. The blood samples were sent
to Sapporo Clinical Laboratory Inc. (Sapporo, Japan) for further
analysis. The adiponectin level was measured using the Human
Total Adiponectin/Acrp30 Quantikine ELISA kit (R&D Systems,
Minneapolis, MN, USA). The body composition and blood pressure
of participants were measured using a body composition analyzer
(InBody device; Biospace Co., Tokyo, Japan) and an automatic blood
pressure monitor (OMRON HEM-780; OMRON Corp., Kyoto, Japan),
respectively.
All participants provided written informed consent before un-
dergoing any study-related tests, and the protocol was approved by
the Ethical Committee of Hokkaido Information University (Hok-
kaido, Japan). The study protocol conformed to the Declaration of
Helsinki.
2.3. Single-nucleotide polymorphisms of the b2-adrenalin receptor
The b2-adrenergic-modulated cardiovascular function is medi-
ated by relaxing vascular smooth muscle, resulting in lowered
blood pressure and a more rapid return of blood to the heart
through the b2-adrenergic receptors.12 It was reported that the
Arg16Gly (þ46 A<G; rs1042713) polymorphism in the b2-
adrenergic receptor gene (ADRb2) has an association with blood
pressure phenotypes.13
In this study, genomic DNAwas extracted from buccal epithelial
cells using the BuccalAmp DNA extraction kit (EPICENTER Bio-
technologies, Madison, WI, USA). Forty-four participants (placebo,
21; test, 23) voluntarily agreed to undergo genotyping. In brief,
after rinsing out the participant's mouth two times with water,
buccal tissue was collected by rolling a collection swab ﬁrmly on
the inside of the cheek. DNA was extracted according to the man-
ufacturer's protocol, and the region harboring a single-nucleotide
polymorphism of interest was ampliﬁed by polymerase chain re-
action (PCR) using speciﬁc primers for each set. Oligonucleotide
sequences for the detection of the ADRb2 gene with Arg16Gly
polymorphism were 50-CACATAACGGGCAGAACGCAC-30 (forward),Table 2
Characteristics of the participants in the placebo and the chicory root extract intake
groups.
Characteristic Chicory Placebo
No. n ¼ 24 n ¼ 23
No. of males (male %) 5 (20.83%) 3 (13.04%)
Age (y) 52.92 ± 11.60 54.30 ± 10.15
Height (cm) 159.69 ± 5.86 158.62 ± 6.61
Body weight (kg) 55.26 ± 9.06 55.93 ± 10.47
BMI (kg/m2) 21.61 ± 2.76 22.20 ± 3.48
Body fat percentage (%) 28.30 ± 6.32 28.68 ± 8.53
Values shown are mean ± standard deviation. Statistical analysis was performed by
analysis of variance for age, height, body weight, and body mass index, and by Chi-
square test for sex.
BMI ¼ body mass index.
Fig. 1. Changes in the level of glucose metabolism parameters from the baseline to the end of intervention in the chicory group (n ¼ 24) and the placebo group (n ¼ 23). (A) Fasting
plasma glucose (FPG). (B) Insulin. (C) Hemoglobin A1c (HbA1c). Values are means ± standard error. *p < 0.05.
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directly sequenced with an ABI310 DNA sequencer (Applied Bio-
systems, Darmstadt, Germany).
2.4. Statistical analysis
The mean and standard deviation of age and other parameters
were calculated for each group. The changes in the values of various
parameters were analyzed using the ManneWhitney U test. The
paired t test was performed at the baseline and at 4 weeks after the
start of the study in each group. Statistical analyses were performed
using IBM SPSS Statistic 19 (IBM, Armonk, NY, USA). The p values
<0.05 were considered to be statistically signiﬁcant. The tendency
values were deﬁned as those that had p values <0.10.
3. Results
3.1. Effects of chicory root extract on glucose metabolism
There were no signiﬁcant differences in age, body weight,
height, or BMI between the control and chicory (菊苣 jú jù) root
groups (Table 2). First, to determine the effect of chicory rootFig. 2. Changes in the level of lipid metabolism parameters from the baseline to the end of
(LDL-Cho). (C) High-density lipoprotein-cholesterol (HDL-Cho). (D) Triglyceride (TG). (E) Adextract on blood glucose metabolism, the levels of FPG, HbA1c,
and fasting insulin were measured. The participants who ingested
the chicory root extract drink for 4 weeks had a signiﬁcant
decrease in the rate of change of HbA1c compared with the pla-
cebo group (change in the range of HbA1c from baseline to
4 weeks: placebo, 0.03% ± 0.02%; chicory, 0.09% ± 0.02%;
p ¼ 0.018; Fig. 1C). No signiﬁcant differences in the FPG or insulin
levels before and after the intervention were observed (Fig. 1A
and B).
3.2. Effects of chicory root extract on lipid metabolism
The effect of chicory root extract on lipid metabolism was also
examined. No signiﬁcant between-group differences in the levels of
total cholesterol (T-Cho), low-density lipoprotein-cholesterol (LDL-
Cho), High-density lipoprotein-cholesterol (HDLCho), Triglyceride
or serum adiponectin were observed (Fig. 2).
3.3. Effects of chicory root extract on body composition
Changes in the body weight, BMI, and body fat percentage of the
participants were analyzed. Although no signiﬁcant differences inthe intervention. (A) Total cholesterol (T-Cho). (B) Low-density lipoprotein-cholesterol
iponectin. Values are means ± standard error.
Fig. 3. Changes in the level of body components from the baseline to the end of the intervention. (A) Body weight. (B) Body index mass (BMI). (C) Body fat percentage. Values are
means ± standard error.
Table 3
Biochemical data and visual analog scale scores.
0 wk 4 wk Change value
FPG (mg/dL) Placebo 87.13 ± 1.79 87.52 ± 2.13 0.39 ± 0.9
Chicory 85.08 ± 2.17 86.45 ± 2.26 1.37 ± 1.11
Insulin (mU/mL) Placebo 3.97 ± 0.39 4.04 ± 0.51 0.07 ± 0.42
Chicory 4.02 ± 0.38 3.91 ± 0.34 0.10 ± 0.34
HbA1c (%) Placebo 5.34 ± 0.07 5.30 ± 0.07 0.03 ± 0.01
Chicory 5.32 ± 0.06 5.22 ± 0.05** 0.09 ± 0.01***
T-Cho (mg/dL) Placebo 233.43 ± 7.14 233.21 ± 7.35 0.21 ± 3.64
Chicory 222.29 ± 6.63 222.87 ± 5.98 0.58 ± 3.88
LDL-Cho (mg/dL) Placebo 143.26 ± 6.24 143.57 ± 6.22 0.96 ± 7.11
Chicory 139.54 ± 5.70 142.00 ± 5.5 7.79 ± 12.73
HDL-Cho (mg/dL) Placebo 80.83 ± 3.50 81.13 ± 3.62 0.30 ± 1.53
Chicory 69.67 ± 3.23 69.46 ± 3.99 0.20 ± 1.07
TG (mg/dL) Placebo 81.39 ± 7.27 82.35 ± 8.81 0.95 ± 7.10
Chicory 101.5 ± 15.27 109.29 ± 25.06 7.79 ± 12.73
Adiponectin
(mg/mL)
Placebo 10.92 ± 1.20 11.04 ± 1.17 0.12 ± 0.20
Chicory 10.54 ± 1.29 10.90 ± 1.33* 0.36 ± 0.27
Body weight
(kg)
Placebo 55.93 ± 2.18 56.57 ± 2.13 0.64 ± 0.60
Chicory 55.26 ± 1.85 55.18 ± 1.81 0.08 ± 0.12
Body fat
percentage (%)
Placebo 28.68 ± 1.78 29.87 ± 1.71 1.19 ± 0.67
Chicory 28.3 ± 1.29 28.09 ± 1.29 0.21 ± 0.44
BMI Placebo 22.2 ± 0.72 22.43 ± 0.71 0.23 ± 0.20
Chicory 21.61 ± 0.56 21.55 ± 0.56 0.05 ± 0.05
SBP in all
participants
(mmHg)
Placebo 120.96 ± 4.72 122.00 ± 3.99 1.04 ± 2.15
Chicory 120.95 ± 4.28 120.54 ± 3.89 4.63 ± 5.46
DBP in all
participants
(mmHg)
Placebo 75.3 ± 2.23 75.35 ± 2.44 0.04 ± 1.31
Chicory 74.61 ± 2.21 74.88 ± 2.09 3.38 ± 3.28
SBP in all
participants
with SNP16A/G
allele (mmHg)
Placebo 114.50 ± 5.79 120.60 ± 6.22* 6.10 ± 2.61
Chicory 127.00 ± 6.87 122.33 ± 6.47 4.67 ± 2.69***
DBP in all
participants
with SNP16A/G
allele (mmHg)
Placebo 71.50 ± 2.69 72.20 ± 2.86 0.70 ± 1.97
Chicory 76.78 ± 3.28 77.11 ± 3.57 0.33 ± 1.65
Defecation rhythm
(mm)
Placebo 55.78 ± 6.28 54.09 ± 6.37 1.70 ± 2.49
Chicory 54.42 ± 6.64 63.54 ± 6.12* 9.13 ± 3.93
Defecation
straining
(mm)
Placebo 65.43 ± 6.47 64.96 ± 5.18 0.48 ± 4.59
Chicory 64.79 ± 5.86 65.13 ± 6.11 0.33 ± 5.03
Defecation
satisfaction
(mm)
Placebo 69.48 ± 5.73 70.91 ± 5.42 1.43 ± 4.25
Chicory 70.38 ± 4.89 74.00 ± 4.71 3.63 ± 5.44
Fecal odor (mm) Placebo 61.09 ± 5.52 62.57 ± 4.99 1.48 ± 3.37
Chicory 73.67 ± 4.12 71.75 ± 4.06 1.92 ± 3.90
Values are mean ± standard error. The comparison was performed by paired t test
for the evaluation values at Week 0 and Week 4 in the same group (*p < 0.05,
**p < 0.01), and by the ManneWhitney U test for the change value comparison
between the placebo and chicory groups (***p < 0.05).
BMI ¼ body mass index; DBP ¼ diastolic blood pressure; Cho ¼ cholesterol;
FPG ¼ fasting plasma glucose; HbA1c ¼ hemoglobin A1c; HDL-Cho ¼ high-density
lipoprotein-cholesterol; LDL-Cho ¼ low-density lipoprotein-cholesterol;
SBP ¼ systolic blood pressure; T-Cho ¼ Total cholesterol, TG ¼ triglyceride.
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chicory groups (Fig. 3), the body fat percentage tended to increase
in the placebo group (28.68 ± 1.78% to 29.87 ± 1.71%; p ¼ 0.074),
whereas there was no change in the body fat percentage of the
chicory group (Table 3).
3.4. Effects of chicory root extract on blood pressure
The blood pressure of the participants was analyzed. No sig-
niﬁcant differences in the level of blood pressure were observed
between the placebo and chicory groups (Fig. 4A and B). However,
we observed that participants with the SNP16A/G allele of ADRb2
who ingested the chicory root extract drink for 4 weeks showed a
signiﬁcant decrease in systolic blood pressure (SBP) compared with
the placebo group (change in SBP from baseline to 4weeks: placebo
group, n ¼ 9: 6.10 ± 2.61 mmHg; chicory group,
n ¼ 10: 4.67 ± 2.69 mmHg; p ¼ 0.018; Fig. 4C and D).
3.5. Effects of chicory root extract on fecal properties
For the evaluation of the effects of chicory root extract on fecal
properties, the participants completed a VAS questionnaire
assessing their defecation rhythm, defecation straining, defecation
satisfaction, and fecal odor (0 mm ¼ worst condition and
100 mm ¼ good condition). The defecation rhythm tended to
improve after ingesting the chicory root extract drink compared
with the placebo drink (change in the VAS score from baseline to
4 weeks: placebo, 1.70 ± 2.49 mm; chicory, 9.13 ± 3.93 mm;
p ¼ 0.051).
3.6. Levels of biomarkers of the liver and renal function after the
ingestion of chicory root extract
The levels of several biomarkers of liver function and renal
function were examined. Minimal changes were observed in the
biomarkers of liver function (alkaline phosphatase, aspartate
aminotransferase, alanine aminotransferase, lactate dehydroge-
nase, and gamma glutamyl transpeptidase) and in the biomarkers
of renal function (blood urea nitrogen and creatinine) after the
ingestion of chicory root extract, suggesting that the ingestion of
chicory root extract has no or minimal unfavorable effects on the
liver and kidneys, even at a dose of 300 mL/d (equivalent to 0.75 g
of inulin/d).
4. Discussion
The results of our randomized, double-blind, placebo-
controlled, parallel-group trial demonstrated the potential effects
Fig. 4. Changes in the systolic blood pressure (SBP) and diastolic blood pressure (DBP) of participants from the baseline to the end of the intervention. (A and B) SBP and DBP values
of all participants: chicory group (n ¼ 24), placebo group (n ¼ 23). (C and D) SBP and DBP for participants with SNP16A/G of b2-adrenalin receptor gene (ADRb2). Chicory group
(n ¼ 9), placebo group (n ¼ 10). Values are means ± standard error. *p < 0.05.
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bolism, and fecal properties. The level of HbA1c was signiﬁcantly
decreased as a result of the 4-week ingestion of chicory root extract.
We also observed that the chicory root extract regimen slightly
improved the VAS score for fecal property and defecation rhythm.
Overall, these results suggest that the chicory root extract improved
hyperglycemia and bowel movement.
A previous clinical study showed that ingesting inulin (10 g/d)
for 8 weeks decreased FPG and HbA1c levels.9 Other reports sug-
gested that the ingestion of oligosaccharides such as inulin
improved glucose metabolism. For example, a carbonated beverage
supplemented with indigestible dextrin suppressed the elevation
of the postprandial blood glucose level through the inhibition of
glucose absorption from the intestine.14 In addition, acarbose, an
antidiabetic drug classiﬁed as an oligosaccharide, suppressed the
elevation of the postprandial blood glucose level by inhibiting the
activities of a-amylase and a-glucosidase.15
Moreover, the ingestion of chicory root extract gradually
increased the postprandial plasma glucose level because inulin is
less susceptible to degradation by a-glucosidase. The aforemen-
tioned ﬁndings and the results of this study suggest that chicory
root extract containing inulin improved HbA1c values by sup-
pressing the postprandial blood glucose level elevation. However,
FPG was not improved in our study (Fig. 1A). It was reported that
the postprandial serum glucose level plays a major role in the
metabolic disequilibrium of patients suffering from mild or mod-
erate hyperglycemia (HbA1c<7.3).16 Further investigation of the
effect of chicory root extract on the postprandial blood glucose and
insulin levels is needed.Although no signiﬁcant between-group differences in the VAS
scores of defecation straining, defecation satisfaction, and fecal
odor were observed in this study, the defecation rhythm was
slightly improved by ingesting the chicory extract drink compared
with the placebo drink (Fig. 5). Inulin-type fructans cannot be
digested easily by salivary and gastric juices because they are
polymers composed mainly of b-(2/1) fructosyl fructose link-
ages.5 In a patient who received radiotherapy, the ingestion of
prebiotic mixtures containing inulin, fructooligosaccharide, and
maltodextrin was evaluated for changes in the populations of
Lactobacillus and Biﬁdobacterium.10 Although our clinical test eval-
uated only fecal properties using a VAS, it is necessary to investigate
the intestinal bacterial ﬂora in feces after the ingestion of chicory
root extract.
We observed no between-group differences in the levels of lipid
metabolism parameters (i.e., T-Cho, LDL-Cho, HDL-Cho, and TG;
Fig. 2). Inulin-type fructans have been tested for their capacity to
modulate lipid metabolism in humans and in several animal
models. In a double-blind, placebo-controlled crossover study with
18 participants, the ingestion of 10 g of inulin/d for 6 weeks
decreased the levels of serum TG and T-Cho.8 The expressions of
acetyl-coenzyme A carboxylase and fatty acid synthase messenger
RNA were also decreased following the ingestion of inulin.5 Our
clinical study did not demonstrate any improvement in lipid
metabolism, probably because it was designed for a shorter period.
However, we found that the level of adiponectin was signiﬁcantly
improved in the chicory root extract group whenwe compared the
baseline and postintervention values (baseline, 10.54 ± 1.29 mg/mL;
postintervention, 10.90 ± 1.33 mg/mL; p ¼ 0.041; Table 3). We need
Fig. 5. Changes in the visual analog scale scores of the participants from the baseline to the end of the intervention. (A) Defecation rhythm. (B) Defecation straining. (C) Defecation
satisfaction. (D) Fecal odor. Values are means ± standard error.
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the ingestion of chicory root extract using in vitro or in vivo
methods.
Neither the chicory root extract drink nor the placebo drink
affected the body composition (body weight, BMI, and body fat
percentage). However, after the 4-week ingestion of the placebo
drink, a slight increase in body fat percentage was observed
(baseline, 28.68 ± 1.78%; postintervention, 29.87 ± 1.71%;
p ¼ 0.074), whereas the chicory root extract drink did not induce
such a change (baseline, 21.6% ± 0.56%; postintervention,
21.55% ± 0.56%, p ¼ 0.833). Adiponectin, an adipocyte-derived
hormone, has an anti-inﬂammatory function. Although its biolog-
ical actions have not been fully investigated, adiponectin showed
improved insulin resistance in hepatocytes through the activation
of adenosine monophosphate-activated kinase.17 In obese patients,
the adiponectin level showed an inverse correlation with visceral
fat decreases.18 Based on the results of our present study, we pro-
pose that the improvement in HbA1c following the 4-week inges-
tion of chicory root extract was related to the reduction of body fat,
thereby increasing the adiponectin level. We need to reconsider the
ingestion period and ingestion volume to better understand the
effects of chicory root extract on the lowering of lipid levels and the
improvement of the body fat percentage.
We also examined the biological action of chicory root extract
with respect to the genotypes at SNP16 of ADRb2. Our ﬁndings
showed that the ingestion of the chicory root extract decreased the
participants' SBP much more effectively among those with an A/Gallele at SNP16. Although the reason for this result has not been
fully investigated, a study using a hypertensive rat model suggested
that mannooligosaccharides were able to suppress an elevation in
blood pressure, and this mechanism involved the inhibition of renal
tubular sodium reabsorption through the suppression of aldoste-
rone secretion.19 Several studies have indicated that certain genes
and their variants can inﬂuence the uptake of nutrient components
from the diet.20 It is of interest to investigate the molecular
mechanisms by which chicory root extract can affect blood pres-
sure through ADRb2.
5. Conclusion
We have demonstrated the possibility that chicory root extract
can modulate hyperglycemia and bowel movement. We used
chicory root extract containing less inulin, which is the main
bioactive component, compared with the prior studies that used
higher concentrations of inulin. Although we need to obtain more
detailed data involving other bioactive components such as
sesquiterpene, our present ﬁndings suggest that the effective use of
chicory root extract could be beneﬁcial for lifestyle-related
diseases.
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